Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery

Lauren Willis, Don Hayes, Heidi - Mansour

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.

Original languageEnglish (US)
Pages (from-to)251-262
Number of pages12
JournalLung
Volume190
Issue number3
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Aerosols
Powders
Inhalation
Nanomedicine
Lung
Dry Powder Inhalers
Mycoses
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Cystic Fibrosis
Surface-Active Agents
Chronic Obstructive Pulmonary Disease
Lung Diseases
Lung Neoplasms
Phospholipids
Tuberculosis
Asthma

Keywords

  • Asthma
  • Chronic obstructive pulmonary disease
  • Cystic fibrosis
  • Lung cancer
  • Pulmonary nanomedicine
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. / Willis, Lauren; Hayes, Don; Mansour, Heidi -.

In: Lung, Vol. 190, No. 3, 06.2012, p. 251-262.

Research output: Contribution to journalArticle

Willis, Lauren ; Hayes, Don ; Mansour, Heidi -. / Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. In: Lung. 2012 ; Vol. 190, No. 3. pp. 251-262.
@article{cc3517c8e58f49628a323b4a8fbe2fd8,
title = "Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery",
abstract = "Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.",
keywords = "Asthma, Chronic obstructive pulmonary disease, Cystic fibrosis, Lung cancer, Pulmonary nanomedicine, Tuberculosis",
author = "Lauren Willis and Don Hayes and Mansour, {Heidi -}",
year = "2012",
month = "6",
doi = "10.1007/s00408-011-9360-x",
language = "English (US)",
volume = "190",
pages = "251--262",
journal = "Lung",
issn = "0341-2040",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery

AU - Willis, Lauren

AU - Hayes, Don

AU - Mansour, Heidi -

PY - 2012/6

Y1 - 2012/6

N2 - Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.

AB - Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.

KW - Asthma

KW - Chronic obstructive pulmonary disease

KW - Cystic fibrosis

KW - Lung cancer

KW - Pulmonary nanomedicine

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84863479128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863479128&partnerID=8YFLogxK

U2 - 10.1007/s00408-011-9360-x

DO - 10.1007/s00408-011-9360-x

M3 - Article

C2 - 22274758

AN - SCOPUS:84863479128

VL - 190

SP - 251

EP - 262

JO - Lung

JF - Lung

SN - 0341-2040

IS - 3

ER -